Overview

Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae

Status:
Unknown status

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

The present study aims at demonstrating the efficacy of temocillin in the treatment of UTI requiring parenteral therapy due to a confirmed ESBL producing or AmpC hyperproducing Enterobacteriaceae, resistant to quinolones and Bactrim® in France. In addition, this study will describe and support the use of high dose (6g/day) of temocillin which could be of interest for the treatment urinary tract infection due to multi-resistant bacteria having high MIC (up to 32 mg/L). The investigators will also evaluate the tolerance of the drug by monitoring the adverse event and the incidence of eventual Clostridium difficile associated infection.

Phase:

Phase 4

Details

Lead Sponsor:

University Hospital, Grenoble

Collaborator:

French National Network of Clinical Research in Infectious Diseases (RENARCI)

Treatments:

Penicillins
Temocillin